Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer
The primary objective of this study is to determine the efficacy of metformin as a repurposed agent in human epidermal growth factor receptor 2 (HER2) positive breast cancer when added to standard neo-adjuvant chemotherapy.
HER2-positive Breast Cancer
DRUG: Taxotere, Carboplatin, Herceptin + Pertuzumab|DRUG: Metformin
Pathologic complete response (pCR), pCR at surgery, Up to 6 weeks after last chemotherapy treatment
The primary objective of this study is to determine the efficacy of metformin as a repurposed agent in human epidermal growth factor receptor 2 (HER2) positive breast cancer when added to standard neo-adjuvant chemotherapy.